GnRH agonist as luteal phase support in assisted reproduction technique cycles: Results of a pilot study

Human Reproduction

Volumn 21, Issue 7, 2006, Pages 1894-1900

  Pirard, C ^a   Donnez, J ^a   Loumaye, E ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

ART; Buserelin; GnRH agonist; GnRH antagonist; Luteal support

Indexed keywords

BUSERELIN; CHORIONIC GONADOTROPIN; ESTRADIOL; GANIRELIX; GONADORELIN AGONIST; HUMAN MENOPAUSAL GONADOTROPIN; LUTEINIZING HORMONE; PROGESTERONE; RECOMBINANT FOLLITROPIN;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ECTOPIC PREGNANCY; EMBRYO; FEMALE; FERTILIZATION IN VITRO; HUMAN; HUMAN CELL; INFERTILITY THERAPY; INTRACYTOPLASMIC SPERM INJECTION; LUTEAL PHASE; OVARY FOLLICLE MATURATION; OVULATION INDUCTION; PILOT STUDY; PREGNANCY; RANDOMIZED CONTROLLED TRIAL; SPONTANEOUS ABORTION; TWIN PREGNANCY;

EID: 33745855889     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/del072     Document Type: Article

References (33)

1. Albano C, Smitz J, Tournaye H, Riethmuller-Winzen H, Van Steirteghem A and Devroey P (1999) Luteal phase and clinical outcome after human menopausal gonadotrophin/gonadotrophin releasing hormone antagonist treatment for ovarian stimulation in in vitro fertilization/ intracytoplasmic sperm injection cycles. Hum Reprod 14,1426-1430.
2. Beckers NG, Macklon NS, Eijkemans MJ, Ludwig M, Felberbaum R, Diedrich K, Bustion S, Loumaye E and Fauser BC (2003) Non-supplemented luteal phase characteristics following the administration of r-hCG, r-hLH or GnRH agonist to induce final oocyte maturation in in vitro fertilisation patients. J Clin Endocrinol Metab 88,4186-4192.
3. Buckett WM, Bentick B and Shaw RW (1998) Induction of the endogenous gonadotrophin surge for oocyte maturation with intra-nasal GnRH analogue (buserelin): Effective minimal dose. Hum Reprod 13 (811-814),1998.
4. Chardonnens D, Sylvan K, Walker D, Bischof P, Sakkas D and Campana A (1998) Triptorelin acetate administration in early pregnancy: Case reports and review of the literature. Eur J Obstet Gynecol Reprod Biol 80,143-149.
5. Elefant E, Biour B, Blumberg-Tick J, Roux C and Thomas F (1995) Administration of a GnRH agonist during pregnancy: Follow-up of 28 pregnancies exposed to triptoreline. Fertil Steril 63,1111-1113.
6. Fauser BC, de Jong D, Olivennes F, Wramsby H, Tay C, Itskovitz-Eldor J and van Hooren HG (2002) Endocrine profile after triggering of final oocyte maturation with GnRH agonist after co-treatment with the GnRH antagonist Ganirelix during ovarian hyperstimulation for in vitro fertilisation. J Clin Endocrinol Metab 87,709-715.
7. Gartner B, Moreno C, Marinaro A, Remohi J, Simon C and Pellicer A (1997) Accidental exposure to daily long-acting gonadotrophin-releasing hormone analogue administration and pregnancy in an in-vitro fertilization cycle. Hum Reprod 12,2557-2559.
8. Golan A, Ron-El R, Herman A, Weinraub Z, Soffer Y and Caspi E (1992) Impaired corpus luteum and other undesired results of pregnancies associated with inadvertent administration of a long-acting agonist of gonadotrophin-releasing hormone. Hum Reprod 7,465-468.
9. Humaidan P, Ejdrup Bredkjaer H, Bungum L, Grondahl ML, Westergaard L and Yding Anderson C (2005) GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: A prospective randomized study. Hum Reprod 20,1213-1220.
10. Kol S (2004) Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome. Fertil Steril 81,1-5.
11. Kolibianakis EM, Bourgain C, Platteau P, Albano C, Van Steirteghem AC and Devroey P (2003) Abnormal endometrial development occurs during the luteal phase of nonsupplemented donor cycles treated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone antagonists. Fertil Steril 80,464-466.
12. Kolibianakis EM, Schultze-Mosgau A, Schroer A, van Steirteghem A, Devroey P, Diedrich K and Griesinger G (2005) A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of hCG in patients undergoing IVF with GnRH antagonists. Hum Reprod 20,2887-2892.
13. Lemay A, Faure N, Labrie F and Fazekas AT (1983) Gonadotroph and corpus luteum responses to two successive intranasal doses of a luteinising hormone-releasing hormone agonist at different days after the mid-cycle luteinising hormone surge. Fertil Steril 39,661-887.
14. Licht P, Russu V and Wildt L (2001) On the role of human chorionic gonadotropin (hCG) in the embryo-endometrial microenvironment: implications for differentiation and implantation. Semin Reprod Med 19,37-47.
15. Loumaye E (1990) The control of endogenous secretion of LH by gonadotrophin-releasing hormone agonists during ovarian hyperstimulation for in-vitro fertilization and embryo transfer. Hum Reprod 5,357-376.
16. Loumaye E, Depreester S, Donnez J and Thomas K (1984) Immunoreactive relaxin surge in the peritoneal fluid of women during the mid-luteal phase. Fertil Steril 42,856-860.
17. Macklon NS and Fauser BCJM (2000) Impact of ovarian hyperstimulation on the luteal phase. J Reprod Fertil 55,101-108.
18. Olivennes F, Fanchin R, Bouchard P, Taieb J and Frydman R (1996) Triggering of ovulation by a GnRH agonist in patients pretreated with a GnRH antagonist. Fertil Steril 66,151-153.
19. Pirard C, Donnez J and Loumaye E (2005) GnRH agonist as a novel luteal support: Results of a randomised, parallel group, feasibility study using intranasal administration of buserelin. Hum Reprod 20,1798-1804.
20. Pritts EA and Atwood AK (2002) Luteal support in infertility treatment: a meta-analysis of the randomized trials. Hum Reprod 17,2287-2299.
21. Rao CV and Lei ZM (2002) Consequences of targeted inactivation of LH receptors. Mol Cell Endocrinol 187,167-174.
22. Ron-El R, Golan A, Herman A, Raziel A, Soffer Y and Caspi E (1990) Mid-luteal gonadodtropin-releasing hormone analog administration in early pregnancy. Fertil Steril 53,572-574.
23. Smitz J, Camus M, Devroey P, Bollen N, Tournaye H and Van Steirteghem AC (1991) The influence of inadvertent intranasal buserelin administration in early pregnancy. Hum Reprod 6,290-293.
24. Smitz J, Bourgain C, Van Waesberghe L, Camus M, Devroey P and Van Steirteghem AC (1993) A prospective randomized study on oestradiol valerate supplementation in addition to intra-vaginal micronized progesterone in buserelin and hMG induced superovulation. Hum Reprod 8,40-45.
25. Stewart EA (2001) Gonadotropins and the uterus: Is there a gonad-independent pathway? J Soc Gynecol Investig 8,319-326.
26. Tavaniotou A, Albano C, Smitz J and Devroey P (2002a) Impact of ovarian stimulation on corpus luteum function and embryonic implantation. J Reprod Immunol 55,123-130.
27. Tavaniotou A, Albano C, Smitz J and Devroey P (2002b) Effect of clomiphene citrate on follicular and luteal phase luteinizing hormone concentrations in in vitro fertilization cycles stimulated with gonadotropins and gonadotropin-releasing hormone antagonist. Fertil Steril 77,733-737.
28. Tesarik J, Hazout A and Mendoza C (2003) Luteinizing hormone affects uterine receptivity independently of ovarian function. Reprod Biomed Online 7,59-64.
29. Tesarik J, Hazout A and Mendoza C (2004) Enhancement of embryo developmental potential by a single administration of GnRH agonist at the time of implantation. Hum Reprod 19,1176-1180.
30. Van Langendonckt A, Demylle D, Wyns C, Nisolle M and Donnez J (2001) Comparison of G1.2/G2.2 and Sydney IVF cleavage/blastocyst sequential media for culture of human embryos: A prospective, randomized, comparative study. Fertil Steril 76,1023-1031.
31. Wilshire GB, Emmi AM, Gagliardi CC and Weiss G (1993) GnRH agonist administration in early human pregnancy is associated with normal outcomes. Fertil Steril 60,980-983.
32. Yen SSC (1991) The human menstrual cycle: Neuroendocrine regulation. In Yen SSC and Jaffe RB (eds) Reproductive Endocrinology, 3rd edn. W.B. Saunders Company, Philadelphia, pp. 273-308.
33. Young DC, Snabes MC and Poindexter AN (1993) GnRH agonist exposure during the first trimester of pregnancy. Obstet Gynecol 81,587-589.